Email
Password

Forgot Password?


Course Overview

This intensive 14.75 hour course offers an in-depth review of the core curriculum in Clinical Lipidology for health care professionals who desire to practice at an advanced level within the field. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.

Online extras include copies of the slides, portable audio, downloadable and online references and additional self-study materials.

Course Curriculum:

  1. Advanced Lipoprotein Metabolism and Genetic Disorders
  2. Advanced Lipidology, Cardiovascular Biomarkers, and Atherosclerosis Imaging
  3. Evidence-Based Nutrition and Ligestule Modifications
  4. Obesity, Metabolic Syndrome and Diabetes Mellitus
  5. Consultative Lipidology and Lipid Management in Special Populations
  6. Pharmacology: Lipid Altering Drugs
  7. Randomized Controlled Trials, Evidence Based Treatment, and Combination Therapy
  8. Complex Cases and Consultative Lipidology

Target Audience This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians with an interest in lipid management.

Objectives and Accreditation

ACTIVITY DATES

Release Date: September 14, 2018
Expiration Date: September 14, 2021

FEE INFORMATION

This course offered to NLA members at a cost of $750.
All other participants may purchase this course at a cost of $1250.

PROGRAM OVERVIEW

This intensive training course offers an in-depth review of the core curriculum in Clinical Lipidology for healthcare professionals who desire to practice at an advanced level within the field. The new case-based, interactive agenda will improve your clinical decision making skills and help prepare you for certification by the American Board of Clinical Lipidology (ABCL) or the Accreditation Council in Clinical Lipidology (ACCL). For those not preparing for certification, the course provides an excellent update and refresher on core concepts in Lipidology. Learn from leading experts, assess your knowledge of lipid science and advance your personal standard of practice.

ACTIVITY TYPE

Enduring Internet Activity

TARGET AUDIENCE

This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advance practice registered nurses, nurse practitioners and registered dietitians with expertise in Lipidology looking for further advanced training.

LEARNING OBJECTIVES

At the conclusion of this activity, participants should be able to:

  • Describe genetic disorders affecting lipoprotein metabolism.
  • Diagnose genetic disorders using lipid profiles.
  • Review the role of biomarkers & subclinical atherosclerosis testing (imaging) in assessment & prevention of ASCVD.
  • Assess differences in clinical practice recommendations & guidelines.
  • Describe evaluation criteria for the classification of patients with metabolic syndrome and/or obesity.
  • Compare and contrast the mechanism of action, pharmacokinetics, and efficacy of approved drugs for the management of dyslipidemia.
  • Identify the frequency and secondary causes of statin intolerance and treatment options for statin intolerant patients.
  • Assess the side effects of lipid-altering drugs.
  • Describe novel therapies in development.
  • Assess the impact of diet, exercise and behavior modifications on cardiovascular risk and risk factors.
  • Interpret evidence from recent literature on dietary cholesterol.
  • Compose a treatment plan for patients incorporating dietary changes.
  • Judge evidence in published literature for its application to clinical practice.
  • Evaluate data from key clinical trials of lipid-altering drug therapies used in cardiovascular disease prevention.
  • Discuss the evidence base for the use of statin and non-statins in the primary & secondary prevention of ASCVD.
  • Evaluate the evidence base for the use of non-statin therapy in combination with moderate to high intensity statin therapy.
  • Review the treatment goals & targets of different lipid guidelines.
  • Appraise treatment approaches for dyslipidemia in specific populations based on age, gender, ethnicity, and cultural variables.
  • Compose a treatment plan for patients with complex lipid disorders.
  • Distinguish roles in a team-based approach to care.
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

CRITERIA FOR SUCCESS

Statements of credit will be awarded based on the participant's attendance and submission of the activity evaluation form. A statement of credit will be available for download upon completion of the online evaluation/claimed credit form. In order to receive credit, participants should complete the online course, score at least 70% on the post-test, and submit the evaluation. The deadline to claim credit is September 14, 2021.
For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at www.mycpemonitor.net within 4 weeks.
Estimated Time for Completion: 14.75 hours

COMMERCIAL SUPPORT

There is no commercial support provided for this activity.

CREDIT DESIGNATION

abim Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.75 AMA PRA Category 1 Credits™ MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Jointly Accredited Provider

In support of improving patient care, this activity has been planned and implemented by The National Lipid Association. The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this Enduring Internet activity for a maximum of 14.75 AMA PRA Category 1 CreditsTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME.

Dietitians
The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 14.5 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL0002.

Pharmacists
Accreditation Council for Pharmacy EducationUniversal Activity Number – JA0007192-0000-18-024-H01-P (Application)
This Activity has been approved for 14.75 contact hour(s) (1.475 CEUs) of the Accreditation Council for Pharmacy Education.

Nursing
The maximum number of hours awarded for this CE activity is 14.7 contact hours.

For the advanced practice nurse, this activity has 2.5 contact hours of pharmacotherapy content.

FACULTY

Program Chair
Harold E. Bays, MD, FACE, FTOS, FNLA*

Medical Director/President
Louisville Metabolic and Atherosclerotic Research Center
Louisville, KY

Program Chair
Terry A. Jacobson, MD, FACP, FNLA*

Professor of Medicine
Director, Office of Health Promotion and Disease Prevention
Emory University
Atlanta, GA

Alan S. Brown, MD, FACC, FAHA, FNLA*
Director, Division of Cardiology
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Clinical Associate Professor
Loyola Stritch School of Medicine
Park Ridge, IL

Anne C. Goldberg, MD, FACP, FNLA*
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Kevin C. Maki, PhD, CLS, FNLA**
Chief Scientist
MB Clinical Research
Glen Ellyn and Chicago, IL

Carl E. Orringer, MD, FACC, FNLA*
Associate Professor of Medicine
University of Miami
School of Medicine
Miami, FL


*Denotes Diplomate, American Board of Clinical Lipidology (ABCL)
**Denotes Diplomate, Accreditation Council for Clinical Lipidology

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity. NLA planners and reviewers have no relevant financial relationships to disclose.

DISCLAIMER

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader's misunderstanding of content.

PERMISSIONS

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Faculty Financial Disclosures

Speaker
Relationship
Company

Bays, Harold
Consultant
Akcea, Alnylam Pharmaceuticals, Amgen, AstraZeneca, Eisai, Eli Lilly & Co., Esperion, Ionis, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Kowa Pharmaceuticals America, Inc., Merck & Co., Inc., Novartis, Orexigen, Procter & Gamble Co., Prosciento, Regeneron, sanofi-aventis, Takeda
Contracted Research
Alere Medical, Allergan PLC, Amarin, Amgen, Arisaph, AstraZeneca, Bristol-Myers Squibb, Catabasis, CymaBay Therapeutics, Dr. Reddy’s Laboratories, Eisai, Elcelyx, Eli Lilly & Co., Esperion, Ferrer/ Chiltern, Gemphire, Gilead, GlaxoSmithKline, iSpecimen, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Nektar, Nichi-Iko Pharmaceuticals, Novartis, Novo Nordisk, Pfizer, Regeneron, sanofi-aventis, Selecta Biosciences, Inc., Takeda, TIMI
Speaker
Amarin, Amgen, AstraZeneca, Eisai, Kowa Pharmaceuticals America, Inc., Orexigen Therapeutics, Regeneron, sanofi-aventis

Brown, Alan
Advisory Board
Akcea, Amgen, Kowa Pharmaceuticals America, Inc., Regeneron, sanofi-aventis
Speaker
Amgen, Kowa Pharmaceuticals America, Inc., Regeneron, sanofi-aventis

Goldberg, Anne
Advisory Board
Esperion, uniQure
Contracted Research
Amarin, Amgen, Genzyme/ ISIS Pharmaceuticals, IONIS, Merck & Co., Inc., Pfizer, Regeneron, Regeneron/sanofi-aventis, The Medicines Company
Consultant
OptumRX , Sanofi/ Regeneron
Scholarly Contributions
Merck & Co., Inc.

Jacobson, Terry
Contracted Research
Amarin, Amgen, Regeneron/ sanofi-aventis
Consultant
Amarin, Amgen, AstraZeneca, Merck & Co., Inc., Regeneron/ sanofi-aventis

Maki, Kevin
Consultant
ACH Food Companies, Akcea, AstraZeneca, Biofortis Innovation Services, DSM, DuPont Nutrition and Health, Egg Nutrition Center, National Cattlemen’s Beef Association, Ocean Spray, Pharmavite, LLC, Sancilio & Company
Speaker
DuPont Nutrition and Health, National Cattlemen’s Beef Association, Pharmavite, LLC, Sancilio & Company

Orringer, Carl
N/A
Nothing to Disclose

Planner Financial Disclosures

NLA
N/A
Nothing to Disclose

Elkins, John Casey
Consultant
Sanofi/ Regeneron
Speaker
Sanofi/ Regeneron

Halli Demeter, Susan
N/A
Nothing to Disclose


Please enter your business email address. We will email you a link that will allow you to select a new password.

Please enter your business email address to start your registration.